140 related articles for article (PubMed ID: 12867100)
21. Comparison of fluconazole, amphotericin B and flucytosine in treatment of a murine model of disseminated infection with Candida glabrata in immunocompromised mice.
Atkinson BA; Bouthet C; Bocanegra R; Correa A; Luther MF; Graybill JR
J Antimicrob Chemother; 1995 May; 35(5):631-40. PubMed ID: 7592176
[TBL] [Abstract][Full Text] [Related]
22. In vitro activities of new and conventional antimycotics against fluconazole-susceptible and non-susceptible Brazilian Candida spp. isolates.
Alves SH; Da Matta DA; Azevedo AC; Loreto ES; Boff E; Santurio JM; Guarro J
Mycoses; 2006 May; 49(3):220-5. PubMed ID: 16681814
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of antifungal susceptibility testing in Candida isolates by Candifast and disk-diffusion method.
Giri S; Kindo AJ
Indian J Pathol Microbiol; 2014; 57(4):595-7. PubMed ID: 25308014
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS.
Mayanja-Kizza H; Oishi K; Mitarai S; Yamashita H; Nalongo K; Watanabe K; Izumi T; Ococi-Jungala ; Augustine K; Mugerwa R; Nagatake T; Matsumoto K
Clin Infect Dis; 1998 Jun; 26(6):1362-6. PubMed ID: 9636863
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the susceptibility of pathogenic Candida species to fluconazole. Fluconazole Global Susceptibility Study Group.
Bille J; Glauser MP
Eur J Clin Microbiol Infect Dis; 1997 Dec; 16(12):924-8. PubMed ID: 9495675
[TBL] [Abstract][Full Text] [Related]
26. Hazards of inadequate fluconazole dosage to treat deep-seated or systemic Candida albicans infection.
Flanagan PG; Barnes RA
J Infect; 1997 Nov; 35(3):295-7. PubMed ID: 9459405
[TBL] [Abstract][Full Text] [Related]
27. Candida albicans brain abscesses in a premature infant treated with amphotericin B, flucytosine and fluconazole.
Kamitsuka MD; Nugent NA; Conrad PD; Swanson TN
Pediatr Infect Dis J; 1995 Apr; 14(4):329-31. PubMed ID: 7603822
[No Abstract] [Full Text] [Related]
28. [Choice and monitoring of the treatment of systemic mycoses. Value and limitations of in vitro tests].
Eloy O; Joly V; Ghnassia JC; Carbon C; Yeni P
Presse Med; 1992 May; 21(20):937-42. PubMed ID: 1322537
[TBL] [Abstract][Full Text] [Related]
29. [Isolation rate and susceptibilities of candida species from blood, vascular catheter, urine and stool].
Tashiro M; Murakami H; Yoshizawa S; Tateda K; Yamaguchi K
Kansenshogaku Zasshi; 2012 Mar; 86(2 Suppl 4):15-20. PubMed ID: 23115940
[TBL] [Abstract][Full Text] [Related]
30. Distribution and antifungal susceptibility of Candida species causing nosocomial candiduria.
Ozhak-Baysan B; Ogunc D; Colak D; Ongut G; Donmez L; Vural T; Gunseren F
Med Mycol; 2012 Jul; 50(5):529-32. PubMed ID: 21988703
[TBL] [Abstract][Full Text] [Related]
31. [CANDIDIASIS GASTROINTESTINAL TRACT].
Kozlova IV; Lekareva LI; Bykova AP; Myalina JN; Ostrovskàja LJ
Eksp Klin Gastroenterol; 2016; (3):40-6. PubMed ID: 27333619
[TBL] [Abstract][Full Text] [Related]
32. Treatment of exogenous Candida endophthalmitis in rabbits with oral fluconazole.
Park SS; D'Amico DJ; Paton B; Baker AS
Antimicrob Agents Chemother; 1995 Apr; 39(4):958-63. PubMed ID: 7786003
[TBL] [Abstract][Full Text] [Related]
33. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
[TBL] [Abstract][Full Text] [Related]
34. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood.
Tortorano AM; Rigoni AL; Biraghi E; Prigitano A; Viviani MA;
J Antimicrob Chemother; 2003 Oct; 52(4):679-82. PubMed ID: 12951345
[TBL] [Abstract][Full Text] [Related]
35. A case of Candida lambica fungemia misidentified as Candida krusei in an intravenous drug abuser.
Vervaeke S; Vandamme K; Boone E; De Laere E; Swinne D; Surmont I
Med Mycol; 2008 Dec; 46(8):853-6. PubMed ID: 18798049
[TBL] [Abstract][Full Text] [Related]
36. [Neonatal Candida infections and the antifungal susceptibilities of the related Candida species].
Altuncu E; Bilgen H; Cerikçioğlu N; Ilki A; Ulger N; Bakır M; Akman I; Ozek E
Mikrobiyol Bul; 2010 Oct; 44(4):593-603. PubMed ID: 21063972
[TBL] [Abstract][Full Text] [Related]
37. In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole.
Clancy CJ; Staley B; Nguyen MH
Antimicrob Agents Chemother; 2006 Oct; 50(10):3496-8. PubMed ID: 17005842
[TBL] [Abstract][Full Text] [Related]
38. [Antifungal susceptibility testing of commensal and pathogenic clinical isolates of oral Candida].
Zhao M; Zhou ZT
Shanghai Kou Qiang Yi Xue; 2006 Apr; 15(2):218-20. PubMed ID: 16685371
[TBL] [Abstract][Full Text] [Related]
39. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients.
Chavanet P; Lopez J; Grappin M; Bonnin A; Duong M; Waldner A; Buisson M; Camerlynck P; Portier H
AIDS; 1994 Jul; 8(7):945-50. PubMed ID: 7946104
[TBL] [Abstract][Full Text] [Related]
40. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
Warnock DW; Johnson EM; Rogers TR
J Antimicrob Chemother; 1998 Sep; 42(3):321-31. PubMed ID: 9786472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
